Dennis Gillings
Executive Chairman @ Novaquest Capital Management
Dennis Gillings is a startup investor at Novaquest Capital Management. Dr. Gillings was born and educated in the United Kingdom. He began providing statistical consulting and data management services to pharmaceutical clients in 1974 during his tenure as Professor of Biostatistics at the University of North Carolina at Chapel Hill. Dr. Gillings founded Quintiles in 1982, which grew out of his consulting activitieswith the pharma industry. He took Quintiles public on NASDAQ in 1994 and led its privatization in 2003. Today, Quintiles is the largest global provider of clinical trials and commercial marketing services to the pharma and biotechnology industry.With more than 30 years of experience in drug development applications and theory, Dr. Gillings has provided expert consultation to numerous companies and health organizations, including the National Cancer Institute, the National Institute for Dental Research and the Institute of Medicine. He has served on several Advisory Boards and Councils including the Cambridge Judge Business School Advisory Board, the Scottish Enterprise Advisory Board and the International Advisory Council in Singapore. He also was the founding Chairman of the Association of Clinical Research Organizations, a Washington-based trade group formed in 2002.He served for more than 15 years as a professor at the University of North Carolina at Chapel Hill and received the Honorary Degree of Doctor of Science in May 2001. - See more at: http://www.quintiles.com/news/biographies/dennis-gillings/#sthash.wvTgIiu2.dpuf
Last updated:
For AI agents: llms.txt
About Novaquest Capital Management
NovaQuest Capital Management, LLC (NovaQuest) manages product and company investments in the global healthcare industry. Its primary focus is structured finance investments in late-stage clinical and commercialized biopharmaceutical products. NovaQuest invests side-by-side with global companies in their most strategic product programs, ensuringalignment with the biopharmaceutical companies. These customized, product transactions are an alternative to standard biopharmaceutical industry deal-making and help companies maximize the value of their product portfolios. In addition, NovaQuest invests in select private equity and other company securities, with a consistent focus on late-stage clinical and commercialized products.The NovaQuest team has worked together for over 12 years, investing over $1 billion into the global healthcare industry. The team began pursuing its strategy in 2000 as an investment group within Quintiles Transnational Holdings Inc. (Quintiles). Today, NovaQuest Capital Management is an independent firm managing global investment capital. It is backed by investors whose relationships with NovaQuest date back to the group’s inception. NovaQuest is meeting the evolving needs of global healthcare companies and its investors with a consistent strategy, developed over multiple years and transactions, that draws on a customized mix of investment and return elements and securities.
Novaquest Capital Management Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Brian Axe
Partner
|
|||
|
Dennis Gillings
Executive Chairman
|
|||
Derek Winstanly
Chief Customer & Governance Officer
|
|||
James Erlinger
General Counsel
|
|||
Paula Brown Stafford
president
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
FAQ
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
